Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 3, 2010, Pages 258-263

  Dirschka, T ^a,b   Bierhoff, E ^b   Pflugfelder, A ^c   Garbe, C ^c  

^a Dermatological Practice Center   (Germany)

^b Institute of Dermatopathology   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Actinic keratosis; Diclofenac; Field cancerization; Skin cancer; Topical treatment

Indexed keywords

CANCER ANTIBODY; DICLOFENAC; EOSIN; HEMATOXYLIN; HYALURONIC ACID; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER; GEL; IMMUNOLOGICAL ADJUVANT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTINIC KERATOSIS; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CANCER GRADING; CANCER REGRESSION; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MITOSIS RATE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TOPICAL TREATMENT; TREATMENT OUTCOME; CELL TRANSFORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECTS; FOLLOW UP; GEL; KERATOSIS, ACTINIC; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; SKIN; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL TRANSFORMATION, NEOPLASTIC; DICLOFENAC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; HYALURONIC ACID; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 76349101673     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03399.x     Document Type: Article

References (21)

1. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007 156 (Suppl. 3 8 12.
2. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000 42 : 4 7.
3. Stockfleth E, Kerl H. Guidelines for the management of actinic keratosis. Eur J Dermatol 2006 16 : 599 606.
4. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000 42 (Suppl. 11 17.
5. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006 155 : 9 22.
6. Shimizu T, Oga A, Murakami T, Muto M. Overexpression of p53 protein associated with proliferative activity and histological degree of malignancy in solar keratosis. Dermatology 1999 199 : 113 118.
7. Barzilai A, Lyakhovitsky A, Trau H, Fogel M, Huszar M. Expression of p53 in the evolution of squamous cell carcinoma: correlation with the histology of the lesion. J Am Acad Dermatol 2007 57 : 669 676.
8. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000 42 : 23 24.
9. Weinberg JM. Topical therapy for actinic keratoses: current and evolving therapies. Rev Recent Clin Trials 2006 1 : 53 60.
10. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronic acid gel. Br J Dermatol 2002 147 : 94 110.
11. Pierard D, Vereecken P, Melot C, Heenen M. Three percent diclofenac in 2.5% hyaluronic acid gel in the treatment of actinic keratoses: a meta-analysis of three recent studies. Arch Dermatol Res 2005 297 : 185 190.
12. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol 2007 157 : 21 24.
13. Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 2008 7 : 167 172.
14. Lober BA, Fenske NA. Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). Am J Clin Dermatol 2004 5 : 395 401.
15. Fournier DB, Gordon GB. Cox-2 in colon cancer: potential targets for chemoprevention. J Cell Biochem 2000 34 (Suppl. 97 102.
16. Buckman SY, Gresham A, Hale P et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998 19 : 723 729.
17. Chan G, Boyle JO, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999 59 : 991 994. (Pubitemid 29135955)
18. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995 17 : 153 156.
19. Warnock GR, Fuller RP, Pelleu GB. Evaluation of 5-fluorouracil in the treatment of actinic keratosis of the lip. Oral Surg Oral Med Oral Pathol 1981 52 : 501 505.
20. TM). J Drugs Dermatol 2004 3 : 401 407.
21. Rivers JK, Wolf J. Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel. Acta Derm Venereol 2007 87 : 188 189.